JPRN-UMIN000005088招募中2 期
A phase II trial of evaluating the benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases and elevated marker of osteoclast activity. - Benefit of zoledronic acid in non-small cell lung cancer patients with bone metastases.
ung Oncology Group in Kyushu, Japan (LOGIK)0 个研究点目标入组 55 人开始时间: 2011年2月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who need radiotherapy or surgery immediately against bone metastases. Prior treatment with Sr-89. Prior bisphosphonates used for cancer. Patients with symptomatic brain metastasis. Severe odontopathy. Interstitial pneumonia on chest x-ray. Patients with active concomitant malignancy. Uncontrolled heart disease, hepatic disease, diabetes mellitus, bleeding. EGFR (+) and planned for EGFR-TKI treatment.
研究者
相似试验
进行中（未招募）
1 期
Study evaluating efficacy of enzalutamide and variants of androgens receptor in metastatic castration resistant prostate cancer patients with visceral diseasemetastatic prostate cancer resistant to castration with visceral diseaseMedDRA version: 20.0Level: LLTClassification code 10007453Term: Carcinoma of the prostate metastaticSystem Organ Class: 100000004864EUCTR2015-004596-72-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI68
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ITAffibody AB110
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-ESAffibody AB110
进行中（未招募）
1 期
Multinational, multicenter, phase 2 study of the efficacy and safety of ABY-035 in treating and preventing relapse/recurrence of disease activity in subjects with non-infectious intermediate, posterior or pan-uveitis.non-infectious intermediate, posterior, or pan-uveitisMedDRA version: 20.0Level: PTClassification code 10046851Term: UveitisSystem Organ Class: 10015919 - Eye disordersEUCTR2020-004964-25-DEAffibody AB20
进行中（未招募）
1 期
A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM) - zoledronic acid in myelofibrosismyelofibrosis with myeloid metaplasiaEUCTR2005-003985-40-BEDepartment of Internal Medicine, University Hospital Gasthuisberg16